Technology Enabled Strategies to Promote Treatment Adherence in Liver Transplant — TEST  

Cirrhosis Clinical Trial

Official title: Technology Enabled Strategies to Promote Treatment Adherence in Liver Transplant

Status Recruiting

Clinical Trial Summary

Liver transplantation is increasingly performed for older adults with multiple comorbidities. Medication adherence is key to maintaining proper function of the transplanted liver and optimize health; however, adhering to post-transplant treatment is complex. This trial will study how available technology combined with transplant center resources and caregiver support can optimize medication adherence, quality of life, and health outcomes among new liver transplant recipients at 3 centers.

Clinical Trial Description

Liver transplant, the only cure for end-stage liver disease, is a costly and limited resource that increases survival. It is increasingly performed among older adults who have a higher burden of comorbidities, medical complexity, and are at risk of non-adherence. In addition, liver transplant recipients must manage complex immunosuppression regimens to maintain graft function. Inadequate immunosuppression adherence is common post-liver transplant and has many adverse consequences including liver graft rejection, graft failure, and re-transplantation. To maintain their health, liver transplant recipients must also self-manage regimens for multiple chronic conditions beyond liver transplant. The TEST Trial intervention is a conceptual framework to address health system and patient level barriers to adherence. By following the Cumulative Complexity Model and the Multiple Chronic Conditions Model, this study focuses on liver transplant recipients and their involved caregivers. The TEST trial leverages the use of electronic health record and Way to Health (W2H) text message system to improve medication adherence. TEST is a 2-arm, patient-randomized controlled trial at three large, diverse transplant centers: University of Pennsylvania (UPENN), Northwestern University (NU); University of Miami (UM). A total of 360 de novo LTRs age 50 or older (n=180 per arm) within 3 months of transplant will be recruited and randomized to intervention versus usual care for 18 months. Interviews will be conducted at baseline, 6, 12, and 18 months. The TEST intervention includes: - Monthly W2H Adherence Assessment & Clinician Alerts - Medication Reminders - Laboratory and Appointment Notifications - Supplemental Self-Management Support The primary objective of the study is to investigate the effectiveness of the TEST Trial to improve adherence to immunosuppressant and non-immunosuppressant medication regimens, functional health status, and health outcomes compared to usual care. Secondary objectives will measure study fidelity and cost effectiveness. ;

Related Conditions & MeSH terms

• Cirrhosis
• End Stage Liver DIsease
• Liver Diseases
• Liver Transplant; Complications
• Medication Adherence

• NCT number: NCT05260268
• Study type: Interventional
• Source: University of Pennsylvania
• Contact: Richard Mason, PharmD
• Phone: (215) 662-3904
• Email: richard.mason@pennmedicine.upenn.edu
• Status: Recruiting
• Phase: N/A
• Start date: December 1, 2022
• Completion date: January 1, 2027